Ampersand to acquire Vibalogics

Ampersand typically invests $10-50m in companies with $10-100m in annual revenues. The firm is currently investing from its Ampersand 2018 fund, which held a final close on $450m in 2018.

This deal follows Ampersand's acquisition of GenDX in May 2019, a healthcare provider based in the Netherlands.

The company plans to strengthen and expand its position in the US and European markets following the transaction. It will also invest in additional process development and GMP manufacturing capabilities.

Company
Founded in 2002, Vibalogics offers process development and the manufacturing of products for biopharmaceutical companies in both the human health and veterinary industries. It employs 50 people at its headquarters in Cuxhaven.

People
Ampersand Capital Partners – David Anderson (general partner).
Vibalogics – Stefan Beyer (CEO).

Advisers
Equity – Goodwin Procter (legal).
Vendor – Goetzpartners (corporate finance); Orrick Herrington & Sutcliffe (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• healthcare
• Germany